HRP20030305B9 - Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function - Google Patents
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionInfo
- Publication number
- HRP20030305B9 HRP20030305B9 HR20030305A HRP20030305A HRP20030305B9 HR P20030305 B9 HRP20030305 B9 HR P20030305B9 HR 20030305 A HR20030305 A HR 20030305A HR P20030305 A HRP20030305 A HR P20030305A HR P20030305 B9 HRP20030305 B9 HR P20030305B9
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- aryl
- alkyl
- heterocyclo
- arylalkyl
- Prior art date
Links
- 102000007399 Nuclear hormone receptor Human genes 0.000 title 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 title 1
- -1 heterocyclic succinimide compounds Chemical class 0.000 title 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 10
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 8
- 125000003107 substituted aryl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000005103 alkyl silyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23351900P | 2000-09-19 | 2000-09-19 | |
| US28443801P | 2001-04-18 | 2001-04-18 | |
| US28473001P | 2001-04-18 | 2001-04-18 | |
| PCT/US2001/019655 WO2002024702A1 (en) | 2000-09-19 | 2001-06-20 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HRP20030305A2 HRP20030305A2 (en) | 2005-04-30 |
| HRP20030305B1 HRP20030305B1 (en) | 2007-12-31 |
| HRP20030305B9 true HRP20030305B9 (en) | 2008-03-31 |
Family
ID=27398441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030305A HRP20030305B9 (en) | 2000-09-19 | 2003-04-18 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20040176324A1 (es) |
| EP (1) | EP1319007B9 (es) |
| JP (1) | JP4966477B2 (es) |
| KR (1) | KR100765670B1 (es) |
| CN (2) | CN1995039A (es) |
| AR (1) | AR035340A1 (es) |
| AT (1) | ATE318822T1 (es) |
| AU (2) | AU6994301A (es) |
| BG (1) | BG107675A (es) |
| BR (1) | BR0113980A (es) |
| CA (1) | CA2423071A1 (es) |
| CZ (1) | CZ2003780A3 (es) |
| DE (1) | DE60117551T2 (es) |
| DK (1) | DK1319007T3 (es) |
| EE (1) | EE200300108A (es) |
| ES (1) | ES2260244T3 (es) |
| GE (1) | GEP20074144B (es) |
| HK (1) | HK1054230B (es) |
| HR (1) | HRP20030305B9 (es) |
| HU (1) | HUP0400455A3 (es) |
| IL (1) | IL155019A0 (es) |
| IS (1) | IS6750A (es) |
| MX (1) | MXPA03002412A (es) |
| MY (1) | MY138531A (es) |
| NO (1) | NO329931B1 (es) |
| NZ (1) | NZ524803A (es) |
| PE (1) | PE20020729A1 (es) |
| PL (1) | PL361707A1 (es) |
| PT (1) | PT1319007E (es) |
| SK (1) | SK4982003A3 (es) |
| TW (1) | TWI305208B (es) |
| UA (1) | UA78686C2 (es) |
| UY (1) | UY26808A1 (es) |
| WO (1) | WO2002024702A1 (es) |
| YU (1) | YU20003A (es) |
| ZA (1) | ZA200302963B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| CZ20024214A3 (cs) * | 2000-06-28 | 2003-04-16 | Bristol-Myers Squibb Company | Selektivní androgen receptorový modulátor, způsob jeho identifikace, jeho konstrukce a použití |
| EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| PL206962B1 (pl) | 2001-12-19 | 2010-10-29 | Bristol Myers Squibb Co | Związek heterocykliczny o budowie skondensowanej |
| TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| KR20050044902A (ko) | 2002-08-12 | 2005-05-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 축합 벤젠 유도체 및 용도 |
| WO2004110978A2 (en) * | 2003-06-10 | 2004-12-23 | Smithkline Beecham Corporation | 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors |
| US7417040B2 (en) * | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| EP1911743B8 (en) * | 2005-08-01 | 2013-01-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
| EP2039695A4 (en) * | 2006-07-11 | 2010-09-15 | Takeda Pharmaceutical | BICYCLIC HETEROCYLIC COMPOUND AND ITS USE |
| US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| US20120135997A1 (en) | 2009-07-17 | 2012-05-31 | Shionogi & Co., Ltd. | Pharmaceutical composition comprising a lactam or benzenesulfonamide compound |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| HUE055562T2 (hu) | 2011-11-23 | 2021-11-29 | Therapeuticsmd Inc | Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| AU2019285034B2 (en) | 2018-06-14 | 2022-09-22 | University Of Florida Research Foundation, Incorporated | Nonmuscle myosin II inhibitors for substance use relapse |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| WO2022061226A1 (en) * | 2020-09-19 | 2022-03-24 | Augusta University Research Institute, Inc. | Compositions and methods for inhibiting trem-1 |
| CN115340483A (zh) * | 2022-08-31 | 2022-11-15 | 南京吉星生物技术开发有限公司 | 一种萘基吡咯啉二酮化合物及其制备方法与它的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3261845A (en) * | 1964-07-14 | 1966-07-19 | Dow Chemical Co | N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide |
| JPS5046697A (es) * | 1973-08-20 | 1975-04-25 | ||
| US5539126A (en) * | 1994-04-20 | 1996-07-23 | Bristol-Myers Squibb Company | Method for preparing homochiral maleimide intermediates, via silylation techniques |
| PT800519E (pt) * | 1994-12-22 | 2004-03-31 | Ligand Pharm Inc | Compostos moduladores de receptores de esteroides e metodos |
| DK0918774T3 (da) * | 1996-06-27 | 2002-05-21 | Ligand Pharm Inc | Androgenreceptormodulatorforbindelser og fremgangsmåder |
| WO1998049555A1 (en) * | 1997-04-29 | 1998-11-05 | The Salk Institute For Biological Studies | Methods for identifying ligands for nuclear hormone receptors |
| US7101681B1 (en) * | 1997-11-21 | 2006-09-05 | Amgen, Inc. | Nuclear hormone receptor drug screens |
| ATE309250T1 (de) * | 1999-09-10 | 2005-11-15 | Novo Nordisk As | Modulatoren der protein tyrosin phosphatase (ptpases) |
| CZ20024214A3 (cs) * | 2000-06-28 | 2003-04-16 | Bristol-Myers Squibb Company | Selektivní androgen receptorový modulátor, způsob jeho identifikace, jeho konstrukce a použití |
-
2001
- 2001-06-20 MX MXPA03002412A patent/MXPA03002412A/es active IP Right Grant
- 2001-06-20 SK SK498-2003A patent/SK4982003A3/sk unknown
- 2001-06-20 CN CNA200710006341XA patent/CN1995039A/zh active Pending
- 2001-06-20 NZ NZ524803A patent/NZ524803A/en unknown
- 2001-06-20 CA CA002423071A patent/CA2423071A1/en not_active Abandoned
- 2001-06-20 AU AU6994301A patent/AU6994301A/xx active Pending
- 2001-06-20 WO PCT/US2001/019655 patent/WO2002024702A1/en active IP Right Grant
- 2001-06-20 JP JP2002529112A patent/JP4966477B2/ja not_active Expired - Fee Related
- 2001-06-20 ES ES01948503T patent/ES2260244T3/es not_active Expired - Lifetime
- 2001-06-20 DE DE60117551T patent/DE60117551T2/de not_active Expired - Lifetime
- 2001-06-20 AT AT01948503T patent/ATE318822T1/de active
- 2001-06-20 US US09/885,381 patent/US20040176324A1/en not_active Abandoned
- 2001-06-20 CN CNB018189350A patent/CN1307181C/zh not_active Expired - Fee Related
- 2001-06-20 EP EP01948503A patent/EP1319007B9/en not_active Expired - Lifetime
- 2001-06-20 EE EEP200300108A patent/EE200300108A/xx unknown
- 2001-06-20 BR BR0113980-0A patent/BR0113980A/pt not_active IP Right Cessation
- 2001-06-20 PL PL36170701A patent/PL361707A1/xx unknown
- 2001-06-20 KR KR1020037004018A patent/KR100765670B1/ko not_active IP Right Cessation
- 2001-06-20 CZ CZ2003780A patent/CZ2003780A3/cs unknown
- 2001-06-20 YU YU20003A patent/YU20003A/sh unknown
- 2001-06-20 DK DK01948503T patent/DK1319007T3/da active
- 2001-06-20 AU AU2001269943A patent/AU2001269943B2/en not_active Ceased
- 2001-06-20 GE GE5206A patent/GEP20074144B/en unknown
- 2001-06-20 HU HU0400455A patent/HUP0400455A3/hu unknown
- 2001-06-20 PT PT01948503T patent/PT1319007E/pt unknown
- 2001-06-20 IL IL15501901A patent/IL155019A0/xx unknown
- 2001-06-20 UA UA2003043564A patent/UA78686C2/uk unknown
- 2001-06-27 TW TW090115632A patent/TWI305208B/zh not_active IP Right Cessation
- 2001-06-28 UY UY26808A patent/UY26808A1/es not_active Application Discontinuation
- 2001-06-28 AR ARP010103101A patent/AR035340A1/es unknown
- 2001-06-28 MY MYPI20013097A patent/MY138531A/en unknown
- 2001-08-22 PE PE2001000656A patent/PE20020729A1/es not_active Application Discontinuation
-
2003
- 2003-03-18 IS IS6750A patent/IS6750A/is unknown
- 2003-03-19 NO NO20031266A patent/NO329931B1/no not_active IP Right Cessation
- 2003-03-26 BG BG107675A patent/BG107675A/bg unknown
- 2003-04-15 ZA ZA200302963A patent/ZA200302963B/en unknown
- 2003-04-18 HR HR20030305A patent/HRP20030305B9/xx not_active IP Right Cessation
- 2003-09-09 HK HK03106433.9A patent/HK1054230B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20030305B9 (en) | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | |
| HU229457B1 (en) | Fungicidal n2-phenylamidine derivatives, intermediates and use thereof | |
| ES2168953A1 (es) | Derivados de oxima y su uso como acidos latentes | |
| JOP20200338A1 (ar) | عامل وقائي أو علاجي للضمور العضلي نخاعي المنشأ | |
| NO990227L (no) | Heterocykliske forbindelser som farmas°ytika | |
| HRP20020175B1 (en) | N-heterocyclikc derivatives as nos inhibitors | |
| MXPA03004958A (es) | Sales onio y su uso como acidos latentes. | |
| MXPA02012569A (es) | Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas. | |
| ES475635A1 (es) | Procedimiento para preparar derivados de imidazol. | |
| CO4970802A1 (es) | Compuesto bencimidazol-5 sustituido con estabilidad mejorada | |
| DK0988312T3 (da) | 17beta-allyloxy(thio)alkyl-androstanderivater til modulering af meiose | |
| ES8702433A1 (es) | Un procedimiento para la preparacion de un compuesto heterociclico sustituido con peptidos. | |
| UA43338C2 (uk) | Похідні бензолу | |
| MY131141A (en) | N-benzyl-indoles, processes for their preparation and pharmaceutical compositions containing them. | |
| ES8200113A1 (es) | Un procedimiento para la preparacion de derivados de cefalosporina. | |
| KR930701454A (ko) | 페넴 화합물 | |
| EA202192557A1 (ru) | Четвертичные амины, содержащие фрагменты изопропилметилфенольного сложного эфира, в качестве противовирусных, антибактериальных и противогрибковых средств | |
| ES456400A1 (es) | Un procedimiento para la preparacion de derivados de tieno- tiacina. | |
| ES279017A1 (es) | Un metodo de producir una 2,4-diaminopirido (2,3-d) pirimidina | |
| GB1063891A (en) | Method for preparation of benzodiazepinones | |
| ES2123785T3 (es) | Nuevo procedimiento de preparacion de acido beta-alcoxi-acrilico. | |
| ES8403891A1 (es) | Un procedimiento para la preparacion de un derivado del acido furiloxazolila-cetico | |
| DE69217148D1 (de) | Isoxazole derivate als lichtschutzmittel | |
| DK113180A (da) | Fremgangsmaade til fremstilling af derivater af dithiepino (1,4) (2,3-c) pyrrol | |
| GB1081635A (en) | Novel amines and a process for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| B9IS | Complete republication of an hr-b document | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090610 Year of fee payment: 9 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20100621 |